Spotlight On... Abbott unveils positive data from a trio of afib trials; VA misappropriated $52M to develop mobile health apps; Analogic to pony up $14.9M corruption fine; and more...

Abbott ($ABT) released positive results from three clinical studies assessing the benefits of focal impulse rotor modulation (FIRM)-guided rotor ablation for atrial fibrillation. The studies involved Abbott's RhythmView tech, which allows doctors to identify rotors, the sources that sustain heart rhythm disorders that are different in each patient. They found that, when used in combination with the traditional treatment for afib, rotor mapping helped 81% of patients stay afib-free at the one-year mark. Release

> The Department of Veterans Affairs misused almost $52 million to fund the development of mobile health apps and "enhance" its Veteran Information Systems and Technology Architecture, violating federal appropriations law. Story

> Analogic ($ALOG) has reached agreements with the SEC, DOJ and the Danish government on a corruption investigation. It will pay approximately $14.9 million in disgorgement, interest, and penalties. Story

> Spine Elements scored 510(k) clearance for its expandable interbody fusion devices. Release

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.